Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Hutchmed

Clinicaltrial registered3 Nov 2026

Hutchmed

3 Nov 2026: Trial registered · HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
3 Nov 2026
Title
HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
Conditions
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07912398
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Hutchmed

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.